Topic Listing for Cytogen

Abnormal Inventory Costs Abstentions
Accounts Payable Accrued Liabilities Accounts Receivable
Acquisition Prostagen Inc Additions Senior Management
Address Notices Selling Securityholder Administration
Adopted 2004 Adopted Various Anti-takeover Provisions Affect Market Price Common
Advanced Magnetics Inc Advanced Magnetics Inc Litigation Settlement Net
Advanced Magnetics Submits Complete Response Approvable Letter Combidex Advertising Costs
Aggregated Option Exercises 2004 End Values Aggregated Option Exercises 2005 End Values
Agreements Advanced Magnetics Inc Allen Bloom
Alphavax Human Vaccines Amendment Termination
Amounts Unless Otherwise Noted Annex
Annual Compensation 2004 Annual Compensation 2005
Annual Retainers Anti-takeover Effects
Antisoma Research Limited Approval 2005 Employee Stock Purchase Plan
Approval 2006 Equity Compensation Plan Approval Amendment Certificate Incorporation Increase Number Authorized Shares
Assignment Form Audit Fees
Audit Finance Committee Board Directors Audit Finance Committee Pre-approval Policy Procedures
Audit-related Fees Axcell Biosciences
Axcell Stock Options Balance Sheet Data
Balance Sheets Base Salary
Basis Consolidation Because Not Intend Pay Paid Cash Dividends Shares
Been Future Subject Patent Litigation Beneficial Ownership Reporting Compliance
Berlex Laboratories Inc Board Directors Attendance Members Meetings
Board Meeting Attendance Bonus
Brachyseed Bristol-myers Squibb Medical Imaging Inc
Broker Non-votes Broker-dealer Status
Business Business Exposes Product Liability Claims Exceed Financial Resources
Business Harmed Certain Agreements Expire Terminated Business Involves Environmental Risks Result Liability
Caphosol Capital Raising
Capital Raising Efforts Dilute Stockholder Interests Capital Raising Shelf Registration Statement
Carrying Value Fixed Intangible Assets Cash Equivalents
Cautionary Statement Certification
Clinical Data Related Combidex Clinical Data Related Psma
Closing Statement Code Business Conduct Ethics
Collaboration Dow Chemical Develop Psma Antibody Treatment Cancer Combidex
Commitments Commitments Contingencies
Committee Meeting Attendance Committees Board
Common Stock Warrants Communication
Communication Independent Directors Comparison Cumulative Total Return
Compensation Committee Board Directors Compensation Committee Interlocks Insider Participation
Compensation Discussion Analysis Compensation Michael Becker
Compensation Objectives Philosophy Competition
Competition Field Intense Likely Increase Competition Related Prostascint
Competition Related Quadramet Competition Related Soltamox
Compliance Internal Revenue Code 162 Components Compensation
Concentration Sales Concentrations Credit Risk
Condensed Statement Cash Flows Consent Independent Registered Public Accounting Firm
Corporate Governance Guidelines Corporation Annual Meeting Stockholders
Cost Product Revenue Cost Product Revenues
Costs Associated Exit Disposal Activities Critical Accounting Policies Estimates
Cytogen Cytogen Announces Definitive Merger Agreement Eusa Pharma 062
Cytogen Corporation Cytogen Raise 140 Through Sale Common Stock Warrants
Cytogen Raise Through Private Placement Common Stock Warrants Date Hereof Until After Effective Neither Nor Subsidiary
Decrease Value Warrant Liabilities Decrease Warrant Liabilities
Decrease Warrant Liability Dennis Langer
Depend Acceptance Products Medical Community Continuation Revenues Depend Attracting Retaining Key Personnel
Depend Sales Quadramet Prostascint Substantially Near-term Revenues Determination Audit Finance Committee Financial Expert
Determination Independence Director Candidates
Director Compensation 2006 Directors
Directors Compensation Dow Chemical
Draximage Inc Dsm Biologics
Eligibility Receive Awards Eligible Employees
Employee Stock Purchase Plan Employees
Employment Contracts Termination Change-in-control Arrangements End Option Values
Entry Material Definitive Agreement 302 Unregistered Sales Entry Material Definitive Agreement 801 Other Events
Equity Compensation Equity Compensation Plan Information
Equity Compensation Plans Not Approved Security Holders Equity Interest Joint Venture
Equity Loss Joint Venture Estimates
Eusa Pharma Exact Name Registrant Specified Charter
Except Set Forth Below Undersigned Not Beneficial Registered Executive Benefits Perquisites
Executive Compensation Executive Officers
Executive Officers Key Employees Executive Sessions Independent Directors
Executive Severance Agreements Exhibits
Expense Reimbursement Explanatory
Failure Party Payors Provide Adequate Coverage Reimbursement Products Fair Value
Fair Value Financial Instruments Fda Committee Votes Not Recommend Approval Proposed Broad
Federal Income Tax Consequences Federal Income Tax Considerations
Fifth Financial Statement Exhibits
Financial Statements Exhibits Foreign Regulatory Approval
Former Name Address Changed Since Last Report Fraud Abuse
Further Clinical Development Related Prostascint Gain Sale Equity Interest Joint Venture
General General Administrative
General Solicitation Neither Nor Knowledge Person Acting Behalf Going Concern Uncertainty
Grants Plan-based Awards Guidance Oversight
Headings Herein Convenience Only Not Constitute Part Agreement Health Care Reimbursement
Held 2005 Held 2006
Held 2007 History Operating Losses Accumulated Deficit Expect Incur Future
Householding Annual Meeting Materials Impairment Intangible Assets
Impairment Long-lived Assets Important Additional Information Filed Sec
Important Information Income Statement Data
Income Tax Benefit Income Taxes
Independent Auditors Independent Auditors Fees Other Matters
Index Index Financial Statements
Information Concerning Solicitation Voting Initiation Quadramet National Bone Pain Registry
Intellectual Property Intellectual Property Difficult Protect
Intellectual Property Position Related Prostascint Intellectual Property Position Related Quadramet
Intellectual Property Position Related Soltamox Intellectual Property Related Prostascint
Interest Income Expense Inventories
Investors Contact James Grigsby
John Bagalay Joseph Mollica
Kevin Bratton Kevin Lokay
Key Employees Large Number Shares Eligible Future Sale Adversely Impact
Laureate Pharma Limited Sales Marketing Distribution Capabilities Products
Liquidity Common Stock Adversely Affected Delisted Nasdaq National Litigation Related Matters
Long Term Compensation Restricted Stock Options Long Term Compensation Stock Options
Long-term Incentive Equity Awards Long-term Liabilities
Manufacturing Agreement Laureate Pharma Manufacturing Supply Distribution Prostascint
Manufacturing Supply Distribution Quadramet Manufacturing Supply Distribution Soltamox
Manufacturing Supply Phase Trials Market Expansion Strategies Prostascint
Marketing Prostascint Marketing Quadramet
Marketing Soltamox Material Features Plan
Matritech Inc Mergers Other Corporate Transactions
Michael Becker Miscellaneous
Name Name Person Filing Proxy Statement Other Registrant
Need Raise Additional Capital Not Available Need Raise Funds Other Through Issuance Equity Securities
Negatively Impacted Future Interpretation Implementation Federal State Fraud Net Loss Per Share
New Accounting Pronouncements New Developments
Nominating Corporate Governance Committee Board Directors Nonstatutory Stock Options
Not Able Implement Axcells Business Plan Notice
Notice Exercise Notwithstanding Foregoing 413 Shall Not Apply Respect Exempt
Now Therefore Resolved Obligations Hereunder Connection Closing Subject Following Conditions Being
Offering Periods Oncoscint
Operating Expenses Option Grants 2004
Option Grants 2005 Option Grants Last
Orphan Drug Act Other Assets
Other Comprehensive Income Other Current Assets
Other Events Other Fees
Other Liquidity Events Other Matters
Other Product Revenue Other Regulations
Other Stock-based Awards Other Stock-based Awards Plan Committee Establish Rules Procedures
Other Strategic Relationships Outstanding Equity Awards Year-end 2006
Overview Part
Participants Solicitation Partners Excellence Sites
Patent Infringement Litigation Settled Payroll Deductions
Performance Graph Place Time Date Meeting
Plan Benefits Plan Distribution
Please Date Sign Return Proxy Card Earliest Convenience Please Detach Mail Envelope Provided
Please Sign Date Return Proxy Card Promptly Using Policy
Potential Oncology Products Subject Risks Failure Inherent Development Potential Payments Executive Officers Termination Connection Change Control
Preclinical Clinical Data Related Psma Preclinical Data Related Therapeutic 7e11-c5 Monoclonal Antibody
Preemptive Similar Rights Subscribe Purchase Securities Subsidiaries Then Princeton New Jersey 08540
Princeton New Jersey 2007 Prior Closing Date Each Purchaser Shall Deliver Cause
Prior Closing Date Shall Deliver Cause Delivered Each Product Contribution Revenues
Products Generally Early Stages Development Commercialization Never Achieve Property Equipment
Proposed Amendment Prostascint
Prostate-specific Membrane Antigen Psma Proxy Properly Executed Voted Manner Directed Herein Undersigned
Proxy Solicited Behalf Board Directors Corporation Annual Meeting Proxy Statement
Psma Development Llc Psma Product Development Program Novel Consequently Inherently Risky
Purchase Price Amount Stock Purchased Purchase Sale
Purchasers Acting Concert Group Respect Purchase Disposition Voting Purpose Plan
Quadramet Quadramet License Fee
Quorum Required Votes Recent Accounting Pronouncements
Reclassification Record Date Voting Securities
Registrants Telephone Number Including Area Code 609 750-8200 Regulation Disclosure
Related Party Transaction Relationships
Rely Heavily Collaborative Partners Rent Expense
Report Audit Finance Committee Board Directors Report Compensation Committee Board Directors
Report Independent Registered Public Accounting Firm Representations Warranties
Representations Warranties Purchasers Each Purchaser Hereby Itself Other Research Development
Research Development Committee Board Directors Respective Obligations Purchasers Hereunder Connection Closing Subject Following
Restrictions Sale Common Stock Officers Retirement Savings Plan
Revenue Recognition Revenues
Revenues Major Customers Revocability Proxies
Risks Associated Manufacture Supply Products Risks Uncertainties
Robert Hendrickson Sale Common Stock Warrants
Sarbanes-oxley Act 2002 Sars
Schedule Holders Schedule Purchasers
Seattle Genetics Inc Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Act 1934 Securities Purchase Agreement
Security Measures Not Protect Unpatented Proprietary Technology See
Selling General Administrative Selling Marketing
Setting Executive Compensation Share-based Payment
Short-term Investments Signature
Signature Page Follows Signature Page Holders Follows
Signature Pages Follow Signatures
Signatures Power Attorney Significant Events 2004
Significant Events 2005 Small Number Customers Account Majority Sales Loss Them
Soltamox Statements Operations
Stephen Carter Stock Awards
Stock Options Stock Price Been Continue Volatile Investment Decline Value
Stock Units Stock-based Compensation
Stockholders Proposals Strategic Relationships Collaborations Licensing Arrangements Related Psma
Strategic Relationships Collaborations Related Prostascint Strategy
Summary Compensation 2004 2003 2002 Summary Compensation 2005 2004 2003
Summary Compensation 2006 Summary Compensation Table
Survival Representations Warranties Contained Herein Shall Survive Closing Table Contents
Tax Consequences Tax Fees
Tax Treatment Participants Therapeutic 7e11-c5 Monoclonal Antibody Cyt-500
Title Class Transfer Restrictions
Unable Comply Applicable Governmental Regulation Not Able Continue Variable Interest Entities
Vote Required Approval Voting
Warrant Liability William Goeckeler Phd
William Thomas Witness Whereof
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki